Replies to post #117132 on Biotech Values

[linhdtu]

Dew, NVS owns 1/3 of Roche. Doesn't that create a conflict of interest ?

-----------------
In their sights are current blockbuster biotech treatments from companies including Roche and Amgen (AMGN).
-----------------

I mean, any gain by Sandoz/Mnta on Roche with generic biologics will be deducted from the loss of Roche mkt cap ?

Perhaps the FOB partner(s) for mnta will have to come from another company than NVS; there are more than one, luckily.